 Kintara Therapeutics Inc NASDAQ:KTRA announced Wednesday that it has enrolled the final patient in the recurrent arm of its ongoing Phase 2 clinical glioblastoma multiforme GBM study of its VAL-083 drug. The recurrent arm of the study addresses patients suffering from GBM who have been pre-treated with the drug temozolomide TMZ prior to disease recurrence, the company said. 